Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus

O'Keefe, James H.; Abuannadi, Mohammad; Lavie, Carl J.; Bell, David S. H.
February 2011
Mayo Clinic Proceedings;Feb2011, Vol. 86 Issue 2, p128
Academic Journal
Type 2 diabetes mellitus (DM) is a major cardiovascular (CV) risk factor and, as such, is considered a coronary artery disease risk equivalent. Although glycemic control is associated with decreased CV events epidemiologically, many prospective clinical trials have failed to conclusively demonstrate that aggressive glycemic control improves the CV prognosis of patients with type 2 DM, especially those with long-standing DM. Many therapies for type 2 DM with widely divergent mechanisms of action are available. Some of these drugs, in addition to their glucose-lowering actions, have properties that may reduce or Increase CV events. Agents that lower both insulin resistance and postprandial hyperglycemia while at the same time avoiding hypoglycemia may be beneficial for CV health. This article reviews the evidence regarding the use of these agents and appropriate glycemic control targets for Improving the adverse CV prognosis associated with type 2 DM. We conducted a systematic review of English articles using MEDLINE and the Coéhrane Controlled Trials Register (1970-2010) using the following search terms: cardiovascular disease, randomized trials, hypoglycemia, and Insulin resistance.


Related Articles

  • The role of insulin resistance in type 2 diabetes. Fisher, Miles // Pulse;3/15/2004, Vol. 64 Issue 11, p69 

    Discusses the fundamental role of insulin resistance in the development of type 2 diabetes in Great Britain. Independent risk factor for cardiovascular disease; Significance of the predictor of disease in primary care.

  • Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy. Anfossi, Giovanni; Trovati, Mariella // Cardiovascular & Hematological Agents in Medicinal Chemistry;2006, Vol. 4 Issue 2, p111 

    The insulin resistance syndrome, which presents among its many facets obesity and type 2 diabetes mellitus, is a major risk factor for cardiovascular events. Thus, therapeutic guidelines recommend multifactorial treatment programs including, especially in the presence of type 2 diabetes,...

  • Sibutramine on Cardiovascular Outcome. SCHEEN, ANDRE J. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS114 

    The article offers a discussion on the perceived cardiovascular disease (CVD) risks of sibutramine and cardiovascular outcomes in overweight/obese patients with or without type 2 diabetes. Considered effective in managing obese patients, sibutramine improves insulin resistance markers, glucose...

  • Management of insulin resistance and type 2 diabetes associated with hepatitis C virus infection. Barrera, Francisco J.; Douglas, Mark W.; George, Jacob // Hot Topics in Viral Hepatitis;2012, Vol. 8 Issue 24, p19 

    Insulin resistance (IR) is present in approximately 50% of patients with chronic hepatitis C (CHC). Beyond the well-described risk of developing diabetes, hypertension, hypertriglyceridemia, and cardiovascular disease, IR in hepatitis C is associated with hepatic inflammation, fibrosis,...

  • Type 2 diabetes and cardiovascular risk in the UK south Asian community. Barnett, A.H.; Dixon, A.N.; Bellary, S.; Hanif, M.W.; O’Hare, J.P.; Raymond, N.T.; Kumar, S. // Diabetologia;Oct2006, Vol. 49 Issue 10, p2234 

    A popular hypothesis for the greater prevalence of type 2 diabetes and cardiovascular disease in UK south Asians is that they have an increased susceptibility of developing insulin resistance in response to certain environmental factors, including obesity and adoption of a sedentary lifestyle....

  • Mother Load A Lucrative Investment Rainy Day Reaction. Barrett, Julia R. // Environmental Health Perspectives;Jul2009, Vol. 117 Issue 7, pA310 

    The article focuses on the research regarding the chronic exposure of arsenic to cause an increased risk of type two diabetes mellitus. The research shows that arsenic can enhance type two diabetes by increasing insulin resistance and impaired insulin production. Meanwhile, it also suggests that...

  • Impaired glucose tolerance/Impaired fasting glucose. Smitherman, Kent; Alper, Brian S. // Cortlandt Forum;Jul2007, Vol. 20 Issue 7, p59 

    The article offers information about the impaired glucose tolerance (IGT) and the impaired fasting glucose (IFG). The causes of IFG and IGT are insulin resistance and relatively insufficient insulin secretion. Patients with obesity or metabolic syndrome are most often affected. It is noted that...

  • The Metabolic Syndrome (Emperor) Wears No Clothes. Kahn, Richard // Diabetes Care;Jul2006, Vol. 29 Issue 7, p1693 

    The article examines whether there is a biological basis for integration of the metabolic syndrome into concepts of insulin resistance, pre-diabetes, and type 2 diabetes. It infers that the presence of the syndrome is associated with a higher risk of diabetes or cardiovascular disease (CVD)....

  • The ENPP1 Q121 Variant Predicts Major Cardiovascular Events in High-Risk Individuals. Bacci, Simonetta; Rizza, Stefano; Prudente, Sabrina; Spoto, Belinda; Powers, Christine; Facciorusso, Antonio; Pacilli, Antonio; Lauro, Davide; Testa, Alessandra; Yuan-Yuan Zhang; Di Stolfo, Giuseppe; Mallamaci, Francesca; Tripepi, Giovanni; Rui Xu; Mangiacotti, Davide; Aucella, Filippo; Lauro, Renato; Gervino, Ernest V.; Hauser, Thomas H.; Copetti, Massimiliano // Diabetes;Mar2011, Vol. 60 Issue 3, p1000 

    OBJECTIVE--Insulin resistance (IR) and cardiovascular disease may share a common genetic background. We investigated the role of IR-associated ENPP1 K121Q polymorphism (rs1044498) on cardiovascular disease in high-risk individuals. RESEARCH DESIGN AND METHODS--A prospective study (average...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics